Advertisement

Cost effectiveness of contraceptives in the United States

      Abstract

      Background

      The study was conducted to estimate the relative cost effectiveness of contraceptives in the United States from a payer's perspective.

      Methods

      A Markov model was constructed to simulate costs for 16 contraceptive methods and no method over a 5-year period. Failure rates, adverse event rates and resource utilization were derived from the literature. Sensitivity analyses were performed on costs and failure rates.

      Results

      Any contraceptive method is superior to ���no method���. The three least expensive methods were the copper-T intrauterine device (IUD) (US$647), vasectomy (US$713) and levonorgestrel (LNG)-20 intrauterine system (IUS) (US$930). Results were sensitive to the cost of contraceptive methods, the cost of an unintended pregnancy and plan disenrollment rates.

      Conclusion

      The copper-T IUD, vasectomy and the LNG-20 IUS are the most cost-effective contraceptive methods available in the United States. Differences in method costs, the cost of an unintended pregnancy and time horizon are influential factors that determine the overall value of a contraceptive method.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Finer L.B.
        • Henshaw S.K.
        Disparities in rates of unintended pregnancy in the United States, 1994 and 2001.
        Perspect Sex Reprod Health. 2006; 38: 90-96
        • Trussell J.
        The cost of unintended pregnancy in the United States.
        Contraception. 2007; 75: 168-170
        • Mosher W.D.
        • Martinez G.M.
        • Chandra A.
        • Abma J.C.
        • Willson S.J.
        Use of contraception and use of family planning services in the United States: 1982���2002.
        Adv Data. 2004; : 1-36
        • Chiou C.F.
        • Trussell J.
        • Reyes E.
        • et al.
        Economic analysis of contraceptives for women.
        Contraception. 2003; 68: 3-10
        • Trussell J.
        • Koenig J.
        • Ellertson C.
        • Stewart F.
        Preventing unintended pregnancy: the cost-effectiveness of three methods of emergency contraception.
        Am J Public Health. 1997; 87: 932-937
        • Chandra A.
        • Martinez G.M.
        • Mosher W.D.
        • Abma J.C.
        • Jones J.
        Fertility, family planning, and reproductive health of U.S. women: data from the 2002 National Survey of Family Growth.
        Vital Health Stat 2. 2005; 23: 1-160
        • Hatcher R.A.
        • Trussell J.
        • Nelson A.L.
        • Cates W.
        • Stewart F.H.
        • Kowal D.
        Contraceptive technology.
        19th rev. ed. Ardent Media, New York (NY)2007
        • Backman T.
        • Rauramo I.
        • Huhtala S.
        • Koskenvuo M.
        Pregnancy during the use of levonorgestrel intrauterine system.
        Am J Obstet Gynecol. 2004; 190: 50-54
        • Backman T.
        • Huhtala S.
        • Blom T.
        • Luoto R.
        • Rauramo I.
        • Koskenvuo M.
        Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17,360 users.
        BJOG. 2000; 107: 335-339
        • Westrom L.
        • Bengtsson L.P.
        • Mardh P.A.
        Incidence, trends, and risks of ectopic pregnancy in a population of women.
        Br Med J (Clin Res Ed). 1981; 282: 15-18
        • Croxatto H.B.
        • Makarainen L.
        The pharmacodynamics and efficacy of Implanon. An overview of the data.
        Contraception. 1998; 58: 91S-97S
        • Peterson H.B.
        • Xia Z.
        • Hughes J.M.
        • Wilcox L.S.
        • Tylor L.R.
        • Trussell J.
        The risk of ectopic pregnancy after tubal sterilization. U.S. Collaborative Review of Sterilization Working Group.
        N Engl J Med. 1997; 336: 762-767
        • Lahteenmaki P.
        • Rauramo I.
        • Backman T.
        The levonorgestrel intrauterine system in contraception.
        Steroids. 2000; 65: 693-697
        • Trussell J.
        • Leveque J.A.
        • Koenig J.D.
        • et al.
        The economic value of contraception: a comparison of 15 methods.
        Am J Public Health. 1995; 85: 494-503
        • Endrikat J.
        • Dusterberg B.
        • Ruebig A.
        • Gerlinger C.
        • Strowitzki T.
        Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study.
        Contraception. 1999; 60: 269-274
        • Jick S.S.
        • Kaye J.A.
        • Russmann S.
        • Jick H.
        Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
        Contraception. 2006; 73: 223-228
        • Fihn S.D.
        • Latham R.H.
        • Roberts P.
        • Running K.
        • Stamm W.E.
        Association between diaphragm use and urinary tract infection.
        JAMA. 1985; 254: 240-245
        • Audet M.C.
        • Moreau M.
        • Koltun W.D.
        • et al.
        Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial.
        JAMA. 2001; 285: 2347-2354
        • Barreiros F.A.
        • Guazzelli C.A.
        • de Araujo F.F.
        • Barbosa R.
        Bleeding patterns of women using extended regimens of the contraceptive vaginal ring.
        Contraception. 2007; 75: 204-208
        • Hooton T.M.
        • Scholes D.
        • Hughes J.P.
        • et al.
        A prospective study of risk factors for symptomatic urinary tract infection in young women.
        N Engl J Med. 1996; 335: 468-474
        • Fihn S.D.
        • Boyko E.J.
        • Normand E.H.
        • et al.
        Association between use of spermicide-coated condoms and Escherichia coli urinary tract infection in young women.
        Am J Epidemiol. 1996; 144: 512-520
      1. Drug topics red book. Thomson Healthcare, Montvale (NJ)2007
      2. Cerner Multum��� Lexicon, 2007.

        • Wolters Kluwer Health
        Price Rx drug price and reference tool (Medi-Span Master Drug Database).
        (Available at) ([Accessed October 2007])
      3. Pharmacy directory: drug prices.
        (Available at) ([Accessed March 2008])
      4. Current procedural terminology (CPT). American Medical Association, Chicago (IL)2007
        • Marquette C.M.
        • Koonin L.M.
        • Antarsh L.
        • Gargiullo P.M.
        • Smith J.C.
        Vasectomy in the United States, 1991.
        Am J Public Health. 1995; 85: 644-649
        • MacKay A.P.
        • Kieke Jr., B.A.
        • Koonin L.M.
        • Beattie K.
        Tubal sterilization in the United States, 1994���1996.
        Fam Plann Perspect. 2001; 33: 161-165
      5. Ingenix DRG Expert. Ingenix, Eden Prairie (MN)2007
        • Finer L.B.
        • Henshaw S.K.
        Abortion incidence and services in the United States in 2000.
        Perspect Sex Reprod Health. 2003; 35: 6-15
        • Henshaw S.K.
        • Finer L.B.
        The accessibility of abortion services in the United States, 2001.
        Perspect Sex Reprod Health. 2003; 35: 16-24
        • Abortion Surveillance ��� United States
        Centers for Disease Control and Prevention. Surveillance summaries. MMWR Morb Mortal Wkly Rep. vol. 55, No. SS-11.
        (Available at) ([Accessed March 2008])
        • March of Dimes
        The healthcare costs of having a baby.
        (Available at) ([Accessed June 2008])
        • Machlin S.R.
        • Rohde F.
        Health care expenses for uncomplicated pregnancies. Research Findings No. 27.
        (Available at) ([Accessed March 2008])
        • Merrill C.
        • Steiner C.
        Hospitalizations related to childbirth, 2003. HCUP Statistical Brief #11. Agency for Healthcare Research and Quality, Rockville, MD.
        (Available at) ([Accessed November 2007])
        • Agency for Healthcare Research and Quality
        Healthcare Cost and Utilization Project (HCUP).
        (Available at) ([Accessed June 2008])
        • Baldaszti E.
        • Wimmer-Puchinger B.
        • Loschke K.
        Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study.
        Contraception. 2003; 67: 87-91
      6. Trussell J, Koenig J, Stewart F, Darroch JE. Medical care cost savings from adolescent contraceptive use. Fam Plann Perspect 1997;29:248���255, 295.

        • National Collaborating Centre for Women & Children's Health
        Long-acting reversible contraception: the effective and appropriate use of long-acting reversible contraception.
        Royal College of Obstetricians and Gynecologists (RCOG), London (UK)2005
        • Mavranezouli I.
        The cost-effectiveness of long-acting reversible contraceptive methods in the UK: analysis based on a decision-analytic model developed for a National Institute for Health and Clinical Excellence (NICE) clinical practice guideline.
        Hum Reprod. 2008; 23: 1338-1345
        • Varney S.J.
        • Guest J.F.
        Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK.
        Pharmacoeconomics. 2004; 22: 1141-1151
        • Phillips C.J.
        Economic analysis of long-term reversible contraceptives. Focus on Implanon.
        Pharmacoeconomics. 2000; 17: 209-221
      7. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64���72, 93.

        • Vaughan B.
        • Trussell J.
        • Kosta K.
        • Singh S.
        • Jones R.
        Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family Growth.
        Contraception. 2008; 78: 271-283
        • Xiao B.
        • Wu S.C.
        • Chong J.
        • Zeng T.
        • Han L.H.
        • Luukkainen T.
        Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia.
        Fertil Steril. 2003; 79: 963-969
        • Trussell J.
        Overstating cost savings from contraceptive use.
        Eur J Contracept Reprod Health Care. 2008; 13: 219-221

      Linked Article